Chan Henry Lee

SVP/General Counsel Lee sells 1,669 shares ($542.4K) via 10b5-1 plan; retains 180,609 derivative options.

Chan Henry Lee sold 1,669 shares at $325.00 on 2026-07-22 under a pre-arranged 10b5-1 trading plan adopted on 2026-05-29, a scheduled transaction rather than a discretionary decision. Post-transaction, his non-derivative holdings became 0 shares, but derivative securities total 180,609 shares across three vested option positions, so his overall exposure to BeOne Medicines remains substantial. His same-ticker history at ONC reveals a consistent pattern: five prior sales in 2025–2026 experienced negative 30-day and 90-day returns (ranging from -8.0% to -14.0%), whereas the current stock stands at $325.90, down 15.4% from its 52-week high and up 17.6% over 30 days. This execution under a pre-arranged 10b5-1 plan removes timing discretion, but the persistent negative post-sale performance in his prior ONC transactions warrants noting as context for equity compensation planning practices at this biotech company.

SVP, General Counsel Lee Chan Henry sells entire 1,660-share stake (1.7K shares) for $580,196.56 via pre-arranged 10b5-1 plan

Lee Chan Henry executed 2 separate sales totaling 1,660 shares for $580,196.56, reducing his position to zero shares. The transaction was executed via a pre-arranged 10b5-1 trading plan adopted on 2025-05-14, meaning the sale was scheduled rather than discretionary. Complete liquidation of executive holdings via scheduled plan warrants routine monitoring but does not inherently signal material deterioration in company outlook or executive-level concern given the automated nature of the transaction.

SVP/General Counsel Lee Chan Henry liquidates entire 10,671 share position at BeOne Medicines for $3,739,107.61 via 4 sales at $347.82–$351.12 on 2025-10-08.

Lee Chan Henry, SVP and General Counsel of BeOne Medicines, executed 4 separate sales totaling 10,671 shares for $3,739,107.61 at a blended average price of $350.40, reducing his holdings from 10,671 shares to zero. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-05-14, and therefore represents a scheduled disposition rather than a discretionary trade. A complete liquidation of an executive's shareholding—particularly by a senior legal officer—typically attracts scrutiny, as it eliminates the executive's direct equity alignment with the company going forward. The scheduled nature of the plan removes the ability to infer timing discretion, but the fact of full exit by a C-suite executive responsible for legal and governance matters remains a material data point for investors monitoring leadership confidence.

SVP General Counsel Lee Chan Henry sold 10,006 shares for $3,257,288.88 via 10b5-1 plan adopted 2025-05-14, eliminating full position

Lee Chan Henry executed 5 separate sales totaling 10,006 shares for $3,257,288.88 on 2025-09-10, reducing holdings from 10,006 shares to 0 shares (a -100.0% reduction in his position). The sales occurred at prices ranging from $325.00 to $327.93 per share across the trading day, with a blended average price of $325.53. This transaction was scheduled under a 10b5-1 trading plan adopted on 2025-05-14, meaning it was pre-arranged and not a discretionary trade. The complete elimination of his equity stake through a planned program removes a previously held incentive position for this senior executive.

SVP/General Counsel Lee Chan Henry sells entire 11,013-share position at BeOne Medicines for $3.3M via 10b5-1 plan

Lee Chan Henry, the SVP and General Counsel of BeOne Medicines, executed 3 separate sales totaling 11,013 shares for $3,308,877.31 at prices ranging from $300.00 to $301.00, leaving him with zero post-transaction holdings. This represents a complete liquidation of his equity stake. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-14, meaning the sales were scheduled in advance rather than discretionary. The elimination of an executive's entire shareholding warrants investor attention regarding potential signals about near-term expectations, though the scheduled nature of the plan limits timing-based inference.